Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Summary

This phase II trial studies how well savolitinib works in treating patients with MET amplified colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2019-07-25

Primary completion

2021-07-31

Completion

2021-12-30

Publications

• Jia J, Moyer A, Lowe M, Bolch E, Kortmansky J, Cho M, Lenz HJ, Kalyan A, Niedzwiecki D, Strickler JH. A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer. J Gastrointest Cancer. 2024 Dec 9;56(1):29. doi: 10.1007/s12029-024-01156-x.

Drugs

Indications